[go: up one dir, main page]

RU2013139670A - APPLICATION OF THE COMBINATION OF ANGIOTENZINE-TURNING ENZYME INHIBITOR AND EPIPHYSIS HORMONE FOR TREATMENT OF ISCHEMIC HEART DISEASE IN ELDERLY PATIENTS - Google Patents

APPLICATION OF THE COMBINATION OF ANGIOTENZINE-TURNING ENZYME INHIBITOR AND EPIPHYSIS HORMONE FOR TREATMENT OF ISCHEMIC HEART DISEASE IN ELDERLY PATIENTS Download PDF

Info

Publication number
RU2013139670A
RU2013139670A RU2013139670/15A RU2013139670A RU2013139670A RU 2013139670 A RU2013139670 A RU 2013139670A RU 2013139670/15 A RU2013139670/15 A RU 2013139670/15A RU 2013139670 A RU2013139670 A RU 2013139670A RU 2013139670 A RU2013139670 A RU 2013139670A
Authority
RU
Russia
Prior art keywords
enzyme inhibitor
administered
melatonin
treatment
heart disease
Prior art date
Application number
RU2013139670/15A
Other languages
Russian (ru)
Other versions
RU2549940C2 (en
Inventor
Наталья Дмитриевна Бунятян
Олег Андреевич Леднев
Original Assignee
Федеральное государственное бюджетное учреждение "Научный центр экспертизы средств медицинского применения" Министерства здравоохранения Российской Федерации (ФГБУ "НЦЭСМП" Минздрава России)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное бюджетное учреждение "Научный центр экспертизы средств медицинского применения" Министерства здравоохранения Российской Федерации (ФГБУ "НЦЭСМП" Минздрава России) filed Critical Федеральное государственное бюджетное учреждение "Научный центр экспертизы средств медицинского применения" Министерства здравоохранения Российской Федерации (ФГБУ "НЦЭСМП" Минздрава России)
Priority to RU2013139670/15A priority Critical patent/RU2549940C2/en
Publication of RU2013139670A publication Critical patent/RU2013139670A/en
Application granted granted Critical
Publication of RU2549940C2 publication Critical patent/RU2549940C2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. Применение фармацевтической комбинации ингибитора ангиотензин-превращающего фермента и гормона эпифиза для раздельного параллельного и/или последовательного введения для лечения ишемической болезни сердца у пожилых больных, отличающееся тем, что в качестве ингибитора ангиотензин-превращающего фермента используют фозиноприл, а в качестве гормона эпифиза используют мелатонин, при этом нормализация состояния пожилого больного происходит на 3-4 день.2. Применение по п. 1, при котором фозиноприл вводят в дозе 10 мг 2 раза в сутки.3. Применение по п. 1, при котором мелатонин вводят в дозе 3 мг 1 раз в сутки.4. Применение по п. 3, при котором мелатонин вводят за 30 мин до сна.1. The use of a pharmaceutical combination of an angiotensin-converting enzyme inhibitor and an pineal gland hormone for separate parallel and / or sequential administration for the treatment of coronary heart disease in elderly patients, characterized in that fosinopril is used as an angiotensin-converting enzyme inhibitor, and an epiphysis hormone is used melatonin, while the normalization of the elderly patient occurs on 3-4 days. 2. The use according to claim 1, wherein fosinopril is administered at a dose of 10 mg 2 times a day. The use according to claim 1, wherein melatonin is administered in a dose of 3 mg once a day. The use of claim 3, wherein melatonin is administered 30 minutes before bedtime.

Claims (4)

1. Применение фармацевтической комбинации ингибитора ангиотензин-превращающего фермента и гормона эпифиза для раздельного параллельного и/или последовательного введения для лечения ишемической болезни сердца у пожилых больных, отличающееся тем, что в качестве ингибитора ангиотензин-превращающего фермента используют фозиноприл, а в качестве гормона эпифиза используют мелатонин, при этом нормализация состояния пожилого больного происходит на 3-4 день.1. The use of a pharmaceutical combination of an angiotensin-converting enzyme inhibitor and an pineal gland hormone for separate parallel and / or sequential administration for the treatment of coronary heart disease in elderly patients, characterized in that fosinopril is used as an angiotensin-converting enzyme inhibitor, and an epiphysis hormone is used melatonin, while the normalization of the elderly patient occurs on 3-4 days. 2. Применение по п. 1, при котором фозиноприл вводят в дозе 10 мг 2 раза в сутки.2. The use according to claim 1, wherein fosinopril is administered at a dose of 10 mg 2 times a day. 3. Применение по п. 1, при котором мелатонин вводят в дозе 3 мг 1 раз в сутки.3. The use according to claim 1, in which melatonin is administered in a dose of 3 mg 1 time per day. 4. Применение по п. 3, при котором мелатонин вводят за 30 мин до сна. 4. The use of claim 3, wherein melatonin is administered 30 minutes before bedtime.
RU2013139670/15A 2013-08-27 2013-08-27 Using combination of angiotensin-converting enzyme inhibitor and pineal hormone for treating ischemic heart disease in elderly patients RU2549940C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2013139670/15A RU2549940C2 (en) 2013-08-27 2013-08-27 Using combination of angiotensin-converting enzyme inhibitor and pineal hormone for treating ischemic heart disease in elderly patients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2013139670/15A RU2549940C2 (en) 2013-08-27 2013-08-27 Using combination of angiotensin-converting enzyme inhibitor and pineal hormone for treating ischemic heart disease in elderly patients

Publications (2)

Publication Number Publication Date
RU2013139670A true RU2013139670A (en) 2015-03-10
RU2549940C2 RU2549940C2 (en) 2015-05-10

Family

ID=53279500

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013139670/15A RU2549940C2 (en) 2013-08-27 2013-08-27 Using combination of angiotensin-converting enzyme inhibitor and pineal hormone for treating ischemic heart disease in elderly patients

Country Status (1)

Country Link
RU (1) RU2549940C2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2134108C1 (en) * 1998-10-06 1999-08-10 Заславская Рина Михайловна Agent for treatment of patient with arterial hypertension, method of treatment of patient with arterial hypertension
RU2294741C1 (en) * 2005-08-08 2007-03-10 Рина Михайловна Заславская Method for treating patients with ischemic cardiac disease, stable stenocardia in combination with arterial hypertension
RU2448701C2 (en) * 2010-07-16 2012-04-27 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Pharmaceutical composition for treating and/or preventing arterial hypertension

Also Published As

Publication number Publication date
RU2549940C2 (en) 2015-05-10

Similar Documents

Publication Publication Date Title
EA202090955A1 (en) METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS
EA201690069A1 (en) THE USE OF HIGH DOSE PRIDOPIDINE FOR THE TREATMENT OF THE HANTINGTON'S DISEASE
MX2020008258A (en) Pediatric niraparib formulations and pediatric treatment methods.
MX2017000628A (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia.
JP2013155188A5 (en)
AR109103A1 (en) TREATMENT OF FABRY'S DISEASE IN PATIENTS NOT TREATED AND PREVIOUSLY TREATED WITH ERT
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
PE20142319A1 (en) MULTIPLE SCLEROSIS TREATMENT WITH A COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE
JOP20200031A1 (en) Methods for treating osteoarthritis with transdermal CBD gel
AR089862A1 (en) USE OF LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH CROHN'S DISEASE IN THOSE WHO FAILS AN ANTI-FACTOR THUMOR NECROSIS THERAPY a (ANTI-TNFa) FIRST LINE
PE20150161A1 (en) USE OF HIGH DOSE LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS
AR103118A1 (en) ANAMORELINE-BASED MEDICAL TREATMENTS
AU2018326364A1 (en) Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease
EA201300421A1 (en) COMBINED THERAPY FOR THE TREATMENT OF HCV INFECTION
EA202090242A1 (en) TREATMENT OF FABRY DISEASE IN FZT-NAIVE AND FZT-TREATED PATIENTS
MA39447B1 (en) Pirlindole or its pharmaceutically acceptable salts for use in medicine
RU2013139670A (en) APPLICATION OF THE COMBINATION OF ANGIOTENZINE-TURNING ENZYME INHIBITOR AND EPIPHYSIS HORMONE FOR TREATMENT OF ISCHEMIC HEART DISEASE IN ELDERLY PATIENTS
EA202090416A1 (en) METHODS FOR TREATING GASTROPARESIS SYMPTOMS USING A VELUSETRAGA
RU2013135325A (en) METHOD FOR CORRECTION AND PREVENTION OF METEOPATHIC REACTIONS IN PATIENTS WITH ARTERIAL HYPERTENSION
RU2011121219A (en) METHOD FOR TREATING INFLAMMATORY DISEASES OF THE PARADONT
AR114012A1 (en) METHOD OF PROVIDING CELIPROLOL THERAPY TO A PATIENT
RU2010129491A (en) METHOD FOR TREATMENT AND PREVENTION OF DENTAL CARIES
EA201592261A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING AGOMELATIN IN THE FORM OF HOMELATIN CRYSTALS WITH ORGANIC ACID
EA201990553A1 (en) APPLICATION OF PRIDOPIDIN FOR TREATMENT OF FUNCTIONAL ABILITY
RU2013147359A (en) METHOD FOR CORRECTION OF THE CONDITION OF BONE TISSUE AND PREVENTION OF THE ORIGIN OF FRACTURES IN PATIENTS WITH CARDIOVASCULAR DISEASES

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20150828